For example, the Her2/neu cancer vaccines combined with granulocyte macrophage-colony stimulating factor (GM-CSF) significantly increased the antigen-specific T responses and prolonged the disease-free survival (DFS) in patients with triple-negative breast cancers [158]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.